文献速递慢性肾脏病血液净化与透析遗传性与小管间质肾病

吡哆醇治疗G170R纯合子PH1患者透析后肾功能恢复三例

Recovery From Dialysis in Patients With Primary Hyperoxaluria Type 1 Treated With Pyridoxine: A Report of 3 Cases.
PubMed 文献 · Am J Kidney Dis · 2020-09-04

本文报告3例G170R纯合子型原发性高草酸尿症1型(PH1)患者,在药理学剂量吡哆醇治疗下成功脱离透析。吡哆醇起始或恢复治疗的中位年龄为37岁,中位剂量为8.8 mg/kg/d,恢复前血液透析中位持续10个月。停透析后中位3个月时eGFR为34 mL/min/1.73m2,肾功能维持中位3.2年,提示该亚组患者肾衰竭可能可逆。

要点

  • G170R纯合子PH1患者使用药理学剂量吡哆醇可能逆转肾衰竭并脱离透析。
  • 吡哆醇中位剂量8.8 mg/kg/d,透析中位10个月后肾功能恢复。
  • 恢复后需监测血浆草酸盐和尿草酸盐排泄,肾功能可维持数年。

核心结论

  • G170R纯合子PH1患者在接受药理学剂量吡哆醇治疗后,肾衰竭可能可逆并成功脱离透析。

研究设计与样本

  • 病例报告,纳入3例G170R纯合子PH1患者,接受药理学剂量吡哆醇治疗并观察透析脱离情况。

主要发现

  • 吡哆醇起始或恢复治疗中位年龄37岁(范围20-53岁),中位日剂量8.8 mg/kg体重(范围6.8-14.0)。
  • 恢复肾功能前血液透析中位持续10个月(范围5-19个月)。
  • 停透析后中位3个月(范围2-46个月)时eGFR为34 mL/min/1.73m2(范围23-52),血浆草酸盐8.8 μmol/L(范围4.6-11.3),尿草酸盐排泄0.93 mmol/d(范围0.47-1.03)。
  • 肾功能在中位3.2年(范围1.3-3.8年)随访期间维持稳定。

临床怎么用

  • 对G170R纯合子PH1合并肾衰竭患者,可考虑药理学剂量吡哆醇治疗并评估肾功能恢复可能。
  • 治疗期间需监测血浆草酸盐浓度和尿草酸盐排泄以评估生化反应。

局限性

  • 仅为3例病例报告,样本量小,结论外推需谨慎。
  • 无对照人群,无法确定吡哆醇与肾功能恢复的因果关系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Primary hyperoxaluria type 1 (PH1) is a genetic disorder characterized by overproduction of oxalate and eventual kidney failure. Kidney failure is usually irreversible in PH1. However, in patients with PH1 homozygous for the G170R mutation (in which the glycine at amino acid 170 is replaced by an arginine), pyridoxine is an enzyme cofactor and decreases urinary oxalate excretion by reducing hepatic oxalate production. We report recovery from dialysis in 3 patients with PH1 homozygous for the G170R mutation in response to pharmacologic-dose pyridoxine treatment. Median age at initiation or resumption of pyridoxine treatment was 37 (range, 20-53) years, and median daily pyridoxine dose was 8.8 (range, 6.8-14.0) mg per kilogram of body weight. Duration of hemodialysis before recovery of kidney function was 10 (range, 5-19) months. Plasma oxalate concentration improved after recovery of kidney function. At a median of 3 (range, 2-46) months following discontinuation of hemodialysis, estimated glomerular filtration rate was 34 (range, 23-52) mL/min/1.73m2, plasma oxalate concentration was 8.8 (range, 4.6-11.3) μmol/L, and urinary oxalate excretion was 0.93 (range, 0.47-1.03) mmol/d. Kidney function was maintained during a median of 3.2 (range, 1.3-3.8) years of follow-up. These observations suggest that kidney failure may be reversible in a subset of patients with PH1 homozygous for the G170R mutation treated with pharmacologic-dose pyridoxine.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Lorenz EC, Lieske JC, Seide BM, et al. Recovery From Dialysis in Patients With Primary Hyperoxaluria Type 1 Treated With Pyridoxine: A Report of 3 Cases. Am J Kidney Dis. 2020. PMID: 32891627. doi:10.1053/j.ajkd.2020.07.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。